You are here:
Archived: betaine anhydrous oral powder (Cystadane)
Advice
Following a full submission
betaine anhydrous (Cystadane®) is not recommended for use within NHS Scotland as adjunctive treatment of homocystinuria in line with the manufacturer’s licence.
The manufacturer did not provide sufficient clinical data to demonstrate efficacy.
Drug Details
| Drug Name: | betaine anhydrous oral powder (Cystadane) |
|---|---|
| SMC Drug ID: | 407/07 |
| Manufacturer: | Orphan Europe (UK) Ltd |
| Indication: | as adjunctive treatment of homocystinuria along with other therapies such as vitamin B6 (pyridoxine), vitamin B12 (cobalamin), folate and a methionine restricted diet |
| BNF Category: | |
| Sub Category: | 9.8 Metabolic disorders |
| Submission Type: | Full submission |
| Status: | Not Recommended |
| Date Advice Published: | 8 October 2007 |
Current Advice
| betaine anhydrous oral powder Cystadane | Resubmission | 9 August 2010 |
Archived Advice
| betaine anhydrous oral powder (Cystadane) | Resubmission | 9 March 2009 |